FDA Advisers Back Authorization of Novavax COVID Shot
The benefits of Novavax’s adjuvanted protein-based COVID-19 vaccine outweigh the risks, the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) said in a near-unanimous vote on Tuesday. With 21 members voting yes, and one abstention, VRBPAC recommended Novavax’s two-dose vaccine for adults, saying that it met the criteria for FDA emergency use authorization (EUA). […]
RSV Vaccine Holds Promise for Pregnant Women
A bivalent protein-based vaccine against respiratory syncytial virus (RSV) administered during pregnancy was safe and led to higher neutralizing antibody responses in mothers, as well as evidence of protection in their infants, an interim analysis of a phase IIb trial found. The geometric mean ratios of 50% neutralizing antibody titers against RSV A and B […]
New COVID-19 nasal spray outperforms current antibody treatments in mice: A single inhaled dose treated or even prevented infection by COVID-19 and its variants
A new protein-based antiviral nasal spray developed by researchers at Northwestern University, University of Washington and Washington University at St. Louis is being advanced toward Phase I human clinical trials to treat COVID-19. Designed computationally and refined in the laboratory, the new protein therapies thwarted infection by interfering with the virus’ ability to enter cells. […]